Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Articles tagged with "Crohn’s disease"

Statin Use Tied to Lower Risk of Inflammatory Bowel Disease

Megan Brooks  |  July 4, 2016

NEW YORK (Reuters Health)—Statin use is associated with a lower risk of developing inflammatory bowel disease (IBD), especially Crohn’s disease in older patients, new research suggests. “Prior studies have suggested that statins can decrease inflammation and may improve IBD in patients who already have the disease. To our knowledge, this is the first study to show…

Biomarkers Differentiate Crohn’s Disease from Ulcerative Colitis

Marilynn Larkin  |  June 4, 2016

NEW YORK (Reuters Health)—Newly identified biomarkers could aid in the diagnosis of inflammatory bowel disease (IBD) and help guide therapy, Canada-based researchers report. Accurately differentiating between Crohn’s disease (CD) and ulcerative colitis (UC) is important for ensuring early and appropriate treatment. However, the conditions can’t be reliably distinguished based on clinical symptoms, site of disease,…

Route of Iron Replacement Doesn’t Impact IBD Activity, Quality of Life

Laura Newman  |  February 20, 2016

NEW YORK (Reuters Health)—The route of iron replacement therapy alters the gut microbiome and metabolomics in patients with inflammatory bowel disease (IBD), but the route is unrelated to disease activity and quality of life, according to a new study. “Crohn’s disease patients are extremely fragile to disturbances and one might speculate about consequences in long-term…

Fungal Microbiota Dysbiosis Seen in Inflammatory Bowel Disease

Anne Harding  |  February 13, 2016

NEW YORK (Reuters Health)—Patients with inflammatory bowel disease (IBD) show imbalance in their fungal intestinal microbiota, according to new findings. “The fungal microbiota is a new actor to take into account in the pathogenesis of IBD and potentially in other diseases,” Dr. Harry Sokol of Hospital Saint-Antoine in Paris, an author of the new study,…

Careful Management Improves Safety of Stem Cell Transplantation in Crohn’s

Will Boggs, MD  |  December 13, 2015

NEW YORK (Reuters Health)—Careful use of antibiotics and corticosteroids can substantially improve the safety of autologous hematopoietic stem transplantation (HSCT) in patients with refractory Crohn’s disease (CD), researchers from Spain report. “Autologous HSCT is feasible but it is associated with severe adverse events and even mortality,” Dr. Elena Ricart from Hospital Clinic de Barcelona tells…

Genetic Data Suggest Dividing IBD into 3 Forms

Will Boggs, MD  |  November 2, 2015

NEW YORK (Reuters Health)—Data from a genetic association study suggest that inflammatory bowel disease (IBD) should be divided into a three-group continuum, rather than the current division between Crohn’s disease and ulcerative colitis. “The current clinical classifications of IBD, while important and useful, are a simplification of the true biological variation of this disease,” Dr….

J&J’s Stelara Succeeds in Phase 3 Crohn’s Disease Trial

Bill Berkrot  |  October 22, 2015

(Reuters)—Johnson & Johnson’s Stelara (ustekinumab) was significantly better than placebo at inducing clinical response and remissions in patients with moderate to severe Crohn’s disease, according to data from a late stage trial, providing ammunition for a potential expanded approval of the medicine. Stelara, a biotech medicine that blocks inflammation, is approved to treat plaque psoriasis…

Relapse Rates High in IBD Patients who Stop Treatment

Megan Brooks  |  September 28, 2015

NEW YORK (Reuters Health)—Inflammatory bowel disease (IBD) patients who achieve remission on treatment may want to go off their IBD medications. But half or more of those who do will have a relapse, according to comprehensive analysis of relevant research. “Based on the studies with extended periods of follow up, relapse rates after cessation appear…

IBD Tied to Higher Risk of Invasive Pneumococcal Disease

David Douglas  |  September 24, 2015

NEW YORK (Reuters Health)—Patients with inflammatory bowel disease (IBD) are at slightly increased risk of invasive pneumococcal disease (IPD), according to Danish researchers. In a paper online Sept. 8 in The American Journal of Gastroenterology, Bjørn Kantsø of Statens Serum Institut in Copenhagen and colleagues note that the inappropriate immune response against infective agents seen in…

Patients Don’t Realize Smoking Worsens Inflammatory Bowel Disease

Lisa Rapaport  |  August 18, 2015

(Reuters Health)—Doctors know smoking can increase the risk for certain common inflammatory bowel diseases (IBD), but many patients haven’t gotten the message, a new study suggests. Out of 239 patients with two common types of IBD (Crohn’s disease and ulcerative colitis) only half were aware of the smoking risks associated with these conditions. “The take-home…

  • « Previous Page
  • 1
  • 2
  • 3
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences